Most Read Articles
Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
4 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 5 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
4 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.

Improving survival with CDK4/6 inhibitors in postmenopausal HR+/HER2-metastatic breast cancer patients

Rachel Soon
Medical Writer
28 Feb 2018

Since the US FDA’s approval of the first cyclin-dependent kinase (CDK) inhibitor in February 2015, the molecules continue to be put to the test as part of the treatment regimen for patients with oestrogen receptor-positive metastatic breast cancers (ER+ MBC), whether as first- or second-line therapies. While overall survival data has yet to mature from clinical trials, the intermediate results appear to support the present use of CDK 4/6 in combination with endocrine therapy in delaying further onset of the disease.

Recent updates on CDK 4/6 trials were reviewed and discussed at the recent European Society for Medical Oncology (ESMO) Congress 2017 in Madrid, Spain, by Dr Alessandra Gennari, medical director of the Division of Medical Oncology of Galliera Hospital, Genoa, Italy; as well as at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting in Chicago, USA, by Dr Ingrid A. Mayer, clinical director of the Breast Cancer Research Program at Vanderbilt-Ingram Cancer Center, Nashville, USA.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
4 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 5 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
4 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.